Biodistribution and improved anticancer effect of NIK-siRNA in combination with 5-FU for hepatocellular carcinoma

Archives of Pharmacal Research

Volumn 34, Issue 1, 2011, Pages 79-86

  Kang, Sung Soo ^a   Cho, Hyun Ah ^a   Kim, Jin Seok ^a  

^a Sookmyung Women's University   (South Korea)

Author keywords

5 FU; Biodistribution; Cationic liposome; Hepatocellular carcinoma; Liver targeting; siRNA

Indexed keywords

FLUOROURACIL; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN INDUCING KINASE; LIPOSOME; PHOSPHOTRANSFERASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG PENETRATION; ENCAPSULATION; ENZYME DEGRADATION; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART; HUMAN; HUMAN CELL; KIDNEY; LIVER; LIVER CELL CARCINOMA; LUNG; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN; TUMOR;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; COMBINED MODALITY THERAPY; FLUOROURACIL; HEPATITIS B; INJECTIONS, INTRAVENOUS; LIPOSOMES; LIVER; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; PERMEABILITY; PROTEIN-SERINE-THREONINE KINASES; RNA, SMALL INTERFERING; TISSUE DISTRIBUTION;

EID: 79955057584     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-011-0109-0     Document Type: Article

References (19)

1. M. Arsura L. G. Cavin 2005 Nuclear factor-kappaB and liver carcinogenesis Cancer Lett. 229 157 169 16125305 10.1016/j.canlet.2005.07.008 1:CAS:528:DC%2BD2MXhtFWms7fP (Pubitemid 41429355)
2. F. Azam A. Koulaouzidis 2008 Hepatitis B virus and hepatocarcinogenesis Ann. Hepatol. 7 125 129 18626429 1:CAS:528:DC%2BD1cXhtlOgsbnF (Pubitemid 351845522)
3. H. A. Cho I. S. Park T. W. Kim Y. K. Oh K. S. Yang J. S. Kim 2009 Suppression of hepatitis B virus-derived human hepatocellular carcinoma by NF-kappaB-inducing kinase-specific siRNA using liver-targeting liposomes Arch. Pharm. Res. 32 1077 1086 19641890 10.1007/s12272-009-1714-z 1:CAS:528: DC%2BD1MXptFGntrs%3D
4. C. Díaz E. Vargas O. Gätjens-Boniche 2006 Cytotoxic effect induced by retinoic acid loaded into galactosyl-sphingosine containing liposomes on human hepatoma cell lines Int. J. Pharm. 325 108 115 16870366 10.1016/j.ijpharm.2006.06.034 (Pubitemid 44573704)
5. Y. Dorsett T. Tuschl 2004 siRNAs: applications in functional genomics and potential as therapeutics Nat. Rev. Drug Discov. 3 318 329 15060527 10.1038/nrd1345 1:CAS:528:DC%2BD2cXis1Gkt74%3D (Pubitemid 38499759)
6. S. M. Elbashir J. Harborth W. Lendeckel A. Yalcin K. Weber T. Tuschl 2001 Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells Nature 411 494 498 11373684 10.1038/35078107 1:CAS:528: DC%2BD3MXkt1ejt7Y%3D (Pubitemid 32494397)
7. G. J. Hannon 2002 RNA interference Nature 418 244 251 12110901 10.1038/418244a 1:CAS:528:DC%2BD38XltFGmu7Y%3D (Pubitemid 34773784)
8. G. J. Hannon J. J. Rossi 2004 Unlocking the potential of the human genome with RNA interference Nature 431 371 378 15372045 10.1038/nature02870 1:CAS:528:DC%2BD2cXnsFaiu7s%3D (Pubitemid 39265678)
9. F. Kamangar G. M. Dores W. F. Anderson 2006 Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world J. Clin. Oncol. 24 2137 2150 16682732 10.1200/JCO.2005.05.2308 (Pubitemid 46655601)
10. S. Kawakami M. Hashida 2007 Targeted delivery systems of small interfering RNA by systemic administration Drug Metab. Pharmacokinet. 22 142 151 17603214 10.2133/dmpk.22.142 1:CAS:528:DC%2BD2sXpslCmtL0%3D
11. J. Kucharczak M. J. Simmons Y. Fan C. Gélinas 2003 To be, or not to be: NF-kappaB is the answer-role of Rel/NFkappaB in the regulation of apoptosis Oncogene 22 8961 8982 14663476 10.1038/sj.onc.1207230 1:CAS:528:DC%2BD3sXpsFOmsrc%3D (Pubitemid 38121698)
12. J. Lupberger E. Hildt 2007 Hepatitis B virus-induced oncogenesis World J. Gastroenterol. 13 74 81 17206756 1:CAS:528:DC%2BD2sXitFSgt7g%3D (Pubitemid 46165464)
13. H. Maeda J. Wu T. Sawa Y. Matsumura K. Hori 2000 Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review J. Control. Release 65 271 284 10699287 10.1016/S0168-3659(99)00248-5 1:CAS:528:DC%2BD3cXhtl2qsLo%3D (Pubitemid 30122932)
14. D. A. Mann F. Oakley 2005 NF-kappaB: a signal for cancer J. Hepatol. 42 610 611 16715553 10.1016/j.jhep.2005.01.007 (Pubitemid 40342946)
15. K. Maruyama O. Ishida T. Takizawa K. Moribe 1999 Possibility of active targeting to tumor tissues with liposomes Adv. Drug Deliv. Rev. 40 89 102 10837782 10.1016/S0169-409X(99)00042-3 1:CAS:528:DyaK1MXmsFajsLc%3D (Pubitemid 29486606)
16. H. L. Pahl 1999 Activators and target genes of Rel/NF-kappaB transcription factors Oncogene 18 6853 6866 10602461 10.1038/sj.onc.1203239 1:CAS:528:DyaK1MXotVyhtL0%3D
17. F. Szoka Jr. D. Papahadjopoulos 1978 Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation Proc. Natl. Acad. Sci. U.S.A. 75 4194 4198 279908 10.1073/pnas.75.9.4194 1:CAS:528:DyaE1MXhvVOhsA%3D%3D (Pubitemid 9025976)
18. D. Treré L. Fiume L. B. De Giorgi G. Di Stefano M. Migaldi M. Derenzini 1999 The asialoglycoprotein receptor in human hepatocellular carcinomas: its expression on proliferating cells Br. J. Cancer 81 404 408 10507763 10.1038/sj.bjc.6690708 (Pubitemid 29458792)
19. W. Wang J. Cassidy V. O'Brien K. M. Ryan E. Collie-Duguid 2004 Mechanistic and predictive profiling of 5-Fluorouracil resistance in human cancer cells Cancer Res. 64 8167 8176 15548681 10.1158/0008-5472.CAN-04-0970 1:CAS:528:DC%2BD2cXpvVGltbY%3D (Pubitemid 39491752)